RxDoctor Payments Data

Nina Chase Bouamoud

Medical · Inverness, FLNPI 1902012966

Payments from drug & device makers

$1,154in general payments, 2019–2025

Across 55 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$134
  • Otsuka America Pharmaceutical, Inc.$134
  • Collegium Pharmaceutical, Inc.$114
  • Boehringer Ingelheim$83
  • Mylan Specialty L.p.$73
  • GSK$69
  • plus $548 from 14 others

What the payments were for

  • Food & beverage$1,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,154 in reported general payments places this provider in the 60th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$96,093
Medicare patients
149
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen811$23,819
Xtampza ErOxycodone Myristate53$22,563
Oxycodone Hcl920$22,237
OxycontinOxycodone Hcl35$18,473
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen445$15,162
Fentanyl85$9,436
Naloxone Hcl134$9,428
Morphine Sulfate ErMorphine Sulfate454$8,853
Morphine Sulfate182$6,483
Gabapentin438$6,228
Tramadol Hcl ErTramadol Hcl67$4,388
Pregabalin215$3,623
Diclofenac Sodium63$3,214
Lidocaine31$2,091
Hydromorphone Hcl81$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$114$22,56353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,031 medical providers in Florida.

Other medical in Inverness

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →